Cookson Peirce & Co. Inc. Buys New Stake in Alector, Inc. (NASDAQ:ALEC)

Cookson Peirce & Co. Inc. acquired a new position in Alector, Inc. (NASDAQ:ALEC) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 20,000 shares of the company’s stock, valued at approximately $160,000.

Several other large investors have also made changes to their positions in the business. Barclays PLC increased its position in Alector by 24.0% in the 3rd quarter. Barclays PLC now owns 138,826 shares of the company’s stock worth $899,000 after buying an additional 26,856 shares during the period. Euclidean Capital LLC raised its stake in Alector by 33.3% during the 3rd quarter. Euclidean Capital LLC now owns 1,307,858 shares of the company’s stock valued at $8,475,000 after purchasing an additional 326,964 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its holdings in Alector by 33.5% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 778,077 shares of the company’s stock valued at $5,042,000 after purchasing an additional 195,411 shares during the period. Acadian Asset Management LLC grew its position in Alector by 68.2% in the 3rd quarter. Acadian Asset Management LLC now owns 153,266 shares of the company’s stock worth $993,000 after purchasing an additional 62,155 shares during the last quarter. Finally, Hsbc Holdings PLC increased its holdings in shares of Alector by 64.8% during the 3rd quarter. Hsbc Holdings PLC now owns 36,807 shares of the company’s stock worth $241,000 after purchasing an additional 14,472 shares during the period. Institutional investors and hedge funds own 85.83% of the company’s stock.

Insider Buying and Selling at Alector

In other Alector news, CEO Arnon Rosenthal sold 18,837 shares of Alector stock in a transaction on Monday, March 4th. The stock was sold at an average price of $6.92, for a total transaction of $130,352.04. Following the completion of the transaction, the chief executive officer now directly owns 2,000,380 shares of the company’s stock, valued at $13,842,629.60. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, CFO Marc Grasso sold 5,716 shares of the firm’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $6.92, for a total value of $39,554.72. Following the completion of the sale, the chief financial officer now directly owns 144,957 shares in the company, valued at $1,003,102.44. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Arnon Rosenthal sold 18,837 shares of the firm’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $6.92, for a total value of $130,352.04. Following the completion of the sale, the chief executive officer now owns 2,000,380 shares of the company’s stock, valued at $13,842,629.60. The disclosure for this sale can be found here. Over the last three months, insiders sold 30,554 shares of company stock valued at $211,434. 14.00% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $41.00 target price on shares of Alector in a research report on Wednesday, February 28th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, Alector has an average rating of “Moderate Buy” and a consensus price target of $14.50.

Alector Stock Down 4.5 %

Shares of ALEC opened at $5.07 on Thursday. The stock has a market cap of $485.45 million, a price-to-earnings ratio of -3.27 and a beta of 0.79. Alector, Inc. has a 12 month low of $3.66 and a 12 month high of $9.06. The company has a 50-day moving average price of $6.23 and a two-hundred day moving average price of $6.21.

Alector (NASDAQ:ALEC) last announced its quarterly earnings results on Tuesday, February 27th. The company reported ($0.49) EPS for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.31. The firm had revenue of $15.19 million during the quarter, compared to analysts’ expectations of $8.35 million. Alector had a negative net margin of 134.34% and a negative return on equity of 77.15%. Equities research analysts expect that Alector, Inc. will post -1.85 EPS for the current fiscal year.

Alector Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.